Skip to Main Content

Paper Details

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Clin Cancer Res
141
2018
CD274, CXCL9, Cancer, IFN, IFN+, IFN+ signature, IFN+-signature NSCLC, Interferon Gamma Messenger RNA, LAG3, NSCLC, Non-Small Cell Lung Carcinoma, PD-L1, Patients, RNA, Tumor, Tumor Biopsies, Urothelial Cancer, advanced-stage non-small cell lung carcinoma, anti-programmed death ligand 1, gene IFN-positive (IFN+) signature, immune cells, liver metastasis, locally advanced or metastatic, mRNA, mRNA signature, messenger RNA, patients, tumor cells, tumor or, urothelial cancer, urothelial cancer tumors

Datasets

Release 1.2